HC Wainwright Issues Negative Outlook for TSE:ONC Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Research analysts at HC Wainwright lowered their FY2028 earnings per share estimates for shares of Oncolytics Biotech in a research report issued to clients and investors on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.56 for the year, down from their prior estimate of $0.57. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2029 earnings at $1.03 EPS.

Separately, Jones Trading cut shares of Oncolytics Biotech from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 16th.

Oncolytics Biotech Stock Down 3.4%

ONC stock opened at C$0.56 on Thursday. Oncolytics Biotech has a one year low of C$0.55 and a one year high of C$2.08. The stock has a market capitalization of C$43.16 million, a PE ratio of -1.56 and a beta of 1.35. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The company has a fifty day moving average of C$0.77 and a 200-day moving average of C$1.05.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.